Safety and efficacy of Direct Oral Anticoagulants in cerebral venous thrombosis: A meta-analysis.
Cerebral venous thrombosis (CVT) is caused by partial or complete occlusion of the major cerebral venous sinuses or the smaller feeding cortical veins which predispose to the risk of venous infarction and hemorrhage. Current guidelines recommend treating CVT with either low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) followed by an oral vitamin K antagonist (VKA) for 3-12 months. Direct oral anticoagulants (DOACs) have already established benefit over warfarin as a long-term treatment of symptomatic venous thromboembolic disorder like deep vein thrombosis (DVT), and pulmonary embolism (PE) given its equal efficacy and better safety profile. The benefit of DOACs over warfarin as a long-term anticoagulation for CVT has likewise been extensively studied, yet it has not been approved as first-line therapy in the current practice. We therefore performed a systematic review and meta-analysis of relevant studies to generate robust evidence regarding the safety and efficacy of DOACs in CVT. This meta-analysis demonstrates that the use of DOACs in CVT has similar efficacy and safety compared to VKAs with better recanalization rate.
['Nepal|Gaurav|G|https://orcid.org/0000-0001-5054-2711', 'Kharel|Sanjeev|S|https://orcid.org/0000-0001-9591-3168', 'Bhagat|Riwaj|R|', 'Ka Shing|Yow|Y|', 'Ariel Coghlan|Megan|M|', 'Poudyal|Prasanta|P|', 'Ojha|Rajeev|R|https://orcid.org/0000-0001-7680-7036', 'Sunder Shrestha|Gentle|G|']
cerebral venous thrombosis CVT DOAC CVST NOAC apixaban dabigatran edoxaban rivaroxaban